Status
Conditions
Treatments
About
The study is designed to confirm the acute safety and performance of the ArterX® Surgical Sealant as a hemostatic agent. The study will collect data in support of publications and future product labeling revisions, to provide additional clinical information on use and further details regarding product safety.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
>18 years of age, Male or female If female, subject is post-menopausal, has no child bearing potential or has a negative serum or urine pregnancy test within 7 days of the index procedure and is practicing abstinence or a highly effective method of contraception for the duration of the study.
The subject or guardian must provide written Informed Consent using a form that is reviewed and approved by the Ethics Committee.
The subject is willing and able to be contacted for 3 months follow-up and attend follow-up visits as needed per protocol.
The subject is determined by the surgeon to be at risk for poor hemostasis.
Exclusion criteria
Subject undergoing emergency surgery. Subject undergoing minimally invasive surgery. Subject has clinically significant medical, psychiatric, or cognitive illness or drug/alcohol abuse that in the opinion of the investigator would affect the subject's safety or compliance with study assessments or follow-up.
Subject has immune system disorders/immunodeficiency or immunosuppression. Subject has participated in another clinical study within 30 days prior to surgery or has received an investigational drug or device within the past 30 days.
Subject is pregnant, may become pregnant or is currently breast feeding
Primary purpose
Allocation
Interventional model
Masking
44 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal